This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tianyin Pharmaceutical's CEO Discusses F3Q 2011 Results - Earnings Call Transcript

Stocks in this article: TPI

FQ3 2011 ending March 31 st 2011 financial highlights – Revenue increased 56.3% year over year to $24.9 million from $15.9 million the year earlier.

Operating income increased 39.9% year over year to $5 million from $3.6 million a year earlier.

Net Income increased 27.7% to $3.7 million year over year from $2.9 million a year earlier.

Earnings per share of $.13 per basic share, or $.12 per diluted share, up from $.11 per basic share or $.09 per diluted share a year earlier. A gain of 19.3% and 35.5% respectively.

Cash and cash equivalents totaled $31.1 million on March 31 st 2011 or $1.10 per basic share in cash.

Sales for the quarter ended March 31 st 2011 was $24.9 million, up 56.3% as compared to $15.9 million for the quarter ended March 31 st 2010.

Although our generic pharmaceutical sales have been under pricing pressure at the beginning of this third quarter, the channel expansion, optimized production facility usage, and the continuous stream of Tianyin Medicine Trading, TMT, distribution revenue supported the quarterly sales growth. With the current hospital coverage at 880 hospitals up from 850 hospitals from the beginning of fiscal year 2011, we are targeting to reach 900 hospitals by the end of fiscal year 2011 ending June 30 th 2011.

Revenues from the top selling products are Gingko Mihuan Oral Liquid, GMOL, $5.6 million. Apu Shuangxin Benorylate Granules, APU, $1.8 million. Azithromycin Tablets, AZI, $.98 million. Xuellian Chongcao Oral Liquid, XLCC, $1.1 million. Qing Re Jie Du Oral Liquid, $.77 million. These products totaled $10.2 million in sales, representing 41.2% of the quarterly revenue.

Cost of Sales for FQ3 was $14 million or 56.2% of sales as compared to $7.5 million or 47.2% of sales a year earlier. Our cost of sales consists of the raw material cost, labor, depreciation and amortization of manufacturing equipment and facilities and other overhead.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,085.72 +55.51 0.31%
S&P 500 2,092.26 +10.38 0.50%
NASDAQ 4,813.8810 +40.4090 0.85%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs